Suppression of adjuvant arthritis by kappa-opioid receptor agonist: Effect of route of administration and strain differences
Samo za registrovane korisnike
1996
Autori
Antić, J.Vasiljević, T.
Stanojević, Stanislava
Vujić, Vesna
Kovačević-Jovanović, Vesna
Đergović, Danica
Miljević, C.
Marković, B.M.
Radulović, Jelena
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
It is well established that K-opioid receptor agonists exert antiinflammatory and antihyperalgesic effects during nonspecific inflammation as well as suppressive effects on the development of humoral and cell-mediated immune responses to foreign antigens. The aim of this study was to investigate the ability of the K-opioid receptor agonist MR 2034 to modulate adjuvant arthritis in the rat. In the first series of experiments, treatments of Wistar rats were performed using several routes of drug administration: intraperitoneal (ip), intracaudal (ic), intracerebroventricular (icy) and intraplantar (ipl). MR 2034 significantly suppressed joint swelling after ip and ic treatment, slightly reduced inflammation after ipl treatment, and did not produce any effect after icy treatment. In the second series of experiments, the suppressive effect of ip injected MR 2034 was investigated using Wistar, Dark August (DA) and Lewis rats. In Wistar rats, MR 2034 significantly decreased the incidence of a...djuvant arthritis, and suppressed mean joint score and aggregate joint score. Similarly, in DA rats treated with MR 2034, mean arthritic score was significantly suppressed, but other clinical parameters were not affected. In Lewis rats, however, ip treatment with MR 2034 failed to produce any suppressive effect on joint disease and even potentiated the initial development of arthritis. These data suggest that immunosuppressive and antiinflammatory action of MR 3034 markedly depend on the route of drug administration and strain susceptibility to opioids.
Ključne reči:
adjuvant arthritis / immunosuppression / kappa-opioid agonist / rat strainsIzvor:
Immunopharmacology, 1996, 34, 2-3, 105-112Izdavač:
- Elsevier, Amsterdam
DOI: 10.1016/0162-3109(96)00114-2
ISSN: 0162-3109
PubMed: 8886854
WoS: A1996VG47300005
Scopus: 2-s2.0-0030245662
Institucija/grupa
TorlakTY - JOUR AU - Antić, J. AU - Vasiljević, T. AU - Stanojević, Stanislava AU - Vujić, Vesna AU - Kovačević-Jovanović, Vesna AU - Đergović, Danica AU - Miljević, C. AU - Marković, B.M. AU - Radulović, Jelena PY - 1996 UR - http://intor.torlakinstitut.com/handle/123456789/65 AB - It is well established that K-opioid receptor agonists exert antiinflammatory and antihyperalgesic effects during nonspecific inflammation as well as suppressive effects on the development of humoral and cell-mediated immune responses to foreign antigens. The aim of this study was to investigate the ability of the K-opioid receptor agonist MR 2034 to modulate adjuvant arthritis in the rat. In the first series of experiments, treatments of Wistar rats were performed using several routes of drug administration: intraperitoneal (ip), intracaudal (ic), intracerebroventricular (icy) and intraplantar (ipl). MR 2034 significantly suppressed joint swelling after ip and ic treatment, slightly reduced inflammation after ipl treatment, and did not produce any effect after icy treatment. In the second series of experiments, the suppressive effect of ip injected MR 2034 was investigated using Wistar, Dark August (DA) and Lewis rats. In Wistar rats, MR 2034 significantly decreased the incidence of adjuvant arthritis, and suppressed mean joint score and aggregate joint score. Similarly, in DA rats treated with MR 2034, mean arthritic score was significantly suppressed, but other clinical parameters were not affected. In Lewis rats, however, ip treatment with MR 2034 failed to produce any suppressive effect on joint disease and even potentiated the initial development of arthritis. These data suggest that immunosuppressive and antiinflammatory action of MR 3034 markedly depend on the route of drug administration and strain susceptibility to opioids. PB - Elsevier, Amsterdam T2 - Immunopharmacology T1 - Suppression of adjuvant arthritis by kappa-opioid receptor agonist: Effect of route of administration and strain differences EP - 112 IS - 2-3 SP - 105 VL - 34 DO - 10.1016/0162-3109(96)00114-2 ER -
@article{ author = "Antić, J. and Vasiljević, T. and Stanojević, Stanislava and Vujić, Vesna and Kovačević-Jovanović, Vesna and Đergović, Danica and Miljević, C. and Marković, B.M. and Radulović, Jelena", year = "1996", abstract = "It is well established that K-opioid receptor agonists exert antiinflammatory and antihyperalgesic effects during nonspecific inflammation as well as suppressive effects on the development of humoral and cell-mediated immune responses to foreign antigens. The aim of this study was to investigate the ability of the K-opioid receptor agonist MR 2034 to modulate adjuvant arthritis in the rat. In the first series of experiments, treatments of Wistar rats were performed using several routes of drug administration: intraperitoneal (ip), intracaudal (ic), intracerebroventricular (icy) and intraplantar (ipl). MR 2034 significantly suppressed joint swelling after ip and ic treatment, slightly reduced inflammation after ipl treatment, and did not produce any effect after icy treatment. In the second series of experiments, the suppressive effect of ip injected MR 2034 was investigated using Wistar, Dark August (DA) and Lewis rats. In Wistar rats, MR 2034 significantly decreased the incidence of adjuvant arthritis, and suppressed mean joint score and aggregate joint score. Similarly, in DA rats treated with MR 2034, mean arthritic score was significantly suppressed, but other clinical parameters were not affected. In Lewis rats, however, ip treatment with MR 2034 failed to produce any suppressive effect on joint disease and even potentiated the initial development of arthritis. These data suggest that immunosuppressive and antiinflammatory action of MR 3034 markedly depend on the route of drug administration and strain susceptibility to opioids.", publisher = "Elsevier, Amsterdam", journal = "Immunopharmacology", title = "Suppression of adjuvant arthritis by kappa-opioid receptor agonist: Effect of route of administration and strain differences", pages = "112-105", number = "2-3", volume = "34", doi = "10.1016/0162-3109(96)00114-2" }
Antić, J., Vasiljević, T., Stanojević, S., Vujić, V., Kovačević-Jovanović, V., Đergović, D., Miljević, C., Marković, B.M.,& Radulović, J.. (1996). Suppression of adjuvant arthritis by kappa-opioid receptor agonist: Effect of route of administration and strain differences. in Immunopharmacology Elsevier, Amsterdam., 34(2-3), 105-112. https://doi.org/10.1016/0162-3109(96)00114-2
Antić J, Vasiljević T, Stanojević S, Vujić V, Kovačević-Jovanović V, Đergović D, Miljević C, Marković B, Radulović J. Suppression of adjuvant arthritis by kappa-opioid receptor agonist: Effect of route of administration and strain differences. in Immunopharmacology. 1996;34(2-3):105-112. doi:10.1016/0162-3109(96)00114-2 .
Antić, J., Vasiljević, T., Stanojević, Stanislava, Vujić, Vesna, Kovačević-Jovanović, Vesna, Đergović, Danica, Miljević, C., Marković, B.M., Radulović, Jelena, "Suppression of adjuvant arthritis by kappa-opioid receptor agonist: Effect of route of administration and strain differences" in Immunopharmacology, 34, no. 2-3 (1996):105-112, https://doi.org/10.1016/0162-3109(96)00114-2 . .